Multiomics study of nonalcoholic fatty liver disease

Summary

This multiomics study leveraged genome-wide association analysis combined with transcriptomic and proteomic data from over 35,000 participants to elucidate the genetic and molecular architecture of nonalcoholic fatty liver disease and cirrhosis. The authors identified 18 genetic variants associated with NAFL, highlighted MTARC1 and GPAM as potential drug targets through discovery of protective loss-of-function variants, and identified 16 putative causal genes predominantly involved in lipid metabolism. The proteomic signature distinguishing NAFL from cirrhosis offers potential for improved noninvasive assessment and therapeutic development.

UK applicability

The proteomic signatures and genetic findings from this predominantly Icelandic and UK Biobank sample are broadly applicable to UK populations given the shared European ancestry and inclusion of UK Biobank participants. The identification of lipid metabolism pathways and drug targets may inform UK clinical practice and pharmaceutical development, though validation in independent UK cohorts would strengthen translational relevance.

Key measures

Sequence variants associated with NAFL and cirrhosis; proton density fat fraction from liver MRI; messenger RNA expression and splicing patterns; 4,907 plasma proteins measured in Icelandic cohort and 1,459 in UK Biobank; hepatocellular carcinoma association

Outcomes reported

The study identified 18 sequence variants associated with nonalcoholic fatty liver disease (NAFL) and 4 with cirrhosis through genome-wide association analysis, and validated putative causal genes through integration of expression, splicing and proteomic data from over 35,000 participants. Multiple plasma proteins were identified that discriminate between NAFL and cirrhosis, suggesting potential for noninvasive diagnostic and therapeutic approaches.

Topic tags